Contineum’s MS drug falls short in Phase II trial
Despite PIPE-307’s failure in RRMS, analysts still have hope for the candidate in major depressive disorder (MDD).
Drug Development
Neurocrine’s depression treatment misses main goal in Phase II study
China accounts for one-fifth of global drugs in development
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Four drugs race for first bispecific ADC approval
NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy
Astellas and Evopoint sign ADC licensing deal
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
